ERBB2 and neoplasm: Therefore, the resistance of MDA-MB-361 and especially MD-MB-453 cells to trastuzumab treatment is most likely due to the insufficient HER2 receptor content since trastuzumab has been repeatedly shown to impair the growth of tumor cells only if the HER2 expression is considerably elevated [26–28].